After Johnson & Johnson's continued efforts to defend its patent for the prostate cancer drug Zytiga proved futile last week, Indian players with generic versions of the drug are trying to gain entry into the US market.

Generic drugs are now giving competition to Zytiga, with SunPharma already launching a specialty drug called Yonsa, with the same formulation, early this year. The drug was approved in combination with another drug (methylprednisolone) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in May. It managed to achieve similar results at half the dosage. There are 10 to 12 other filers for generic drugs so far- Mylan, Glenmark, Dr Reddy's, Wockhardt, Hikma, Amneal, West-Ward, Amerigen, Argentum Pharma, Par Pharmaceutical, Apotex, Citron. Two of these have even received a tentative approval. 

Information for the article was sourced from Business Standard. Find the original article by clicking here.